Prosecution Insights
Last updated: April 19, 2026

Ascentage Pharma Group Corp Limited

4 pending office actions

Portfolio Summary

4
Total Pending OAs
1
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18269301 METHODS OF TREATING MULTIPLE SCLEROSIS SHIM, DAVID M. 1626 Non-Final OA Jun 23, 2023
18006494 COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS BARSKY, JARED 1628 Final Rejection Jan 23, 2023
17921257 METHODS FOR SYNTHESIZING N-(PHENYLSULFONYL)BENZAMIDE COMPOUNDS AND INTERMEDIATES THEREOF HEITMEIER, KENDALL NICOLE 1621 Non-Final OA Oct 25, 2022
17781699 COMBINATION OF IAP INHIBITORS AND PARP OR MEK INHIBITORS OR OTHER CHEMOTHERAPEUTIC AGENTS HEITMEIER, KENDALL NICOLE 1621 Non-Final OA Jun 01, 2022

Managing Ascentage Pharma Group Corp Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month